I guess at least a partial explanation is that they have to display to BARDA that Novavax has met the requirements of being able to produce 50 million doses in 6 months, (if I recall). Just promising or showing a plan would not suffice, I would think, but they must have to really have things set up. Not to deny the possibility of other reasons.
Col. Sherman T. Potter: Why are you dressed like an Italian usher?
Colonel Flagg: Can you keep a secret?
Col. Sherman T. Potter: I'd like to think so.
Colonel Flagg: I'm disguised as Ling Chow. A Chinese double agent.
Col. Sherman T. Potter: Funny, you don't look Chinese.
Colonel Flagg: Neither would Ling Chow if he was dressed like this. You follow?
Col. Sherman T. Potter: As far as I'd like to.
Colonel Flagg: I'm off.
Col. Sherman T. Potter: I couldn't have said it better myself.
The reemergence of H7N9 in China during the past month has reinforced the need for a vaccine. Candidates from Chinese and Taiwanese manufacturers have grabbed the headlines recently, but now a U.S. player, Novavax ($NVAX), has joined the race with positive Phase I data.
Novavax reported a summary of the results in a letter to The New England Journal of Medicine. The trial enrolled 284 people in Australia and gave them a placebo or one of 6 H7N9 vaccine formulations. Based on the antibody responses, Novavax thinks two shots of 5µg of antigen will protect four-in-five people when given with 60 ISCO units of CSL's Iscomatrix adjuvant. Higher antigen doses were given without the adjuvant, but using smaller quantities increases the number of available vaccines.
In a pandemic situation, when manufacturing can be a bottleneck, this is important, and observers are encouraged by the data. "These are very preliminary results, but it appears for the first time that we may have a vaccine that would work against an outbreak [of avian flu]. This is a very important milestone. We have a promising vaccine where before we had none," Biomedical Advanced Research and Development Authority (BARDA) director Robin Robinson told Reuters.
Robinson also talked up the expected benefits of using virus-like particle vaccines instead of traditional egg-based production methods. The response to swine flu in 2009 was hamstrung by production delays, the fixing of which the U.S. government has prioritized. Computer models used by BARDA show Novavax could produce a vaccine 12 weeks after the start of an outbreak and have 50 million doses available within four months.
Read more: Novavax presents positive Phase I data for H7N9 vaccine - FierceVaccines
Piper Jaffray & Co. Edward A. Tenthoff
"is this something you would want to partner near term or
take further along yourself?"
"I think that we have concluded that we can best move the program
forward by keeping control of it ourselves, at least through phase II's,
and (ask me) sometime down in the future whether we take it into phase III's
or not "
The future should be very entertaining.
the four strains were-
A/Christchurch/16/2010 H1N1 for ( A/California/7/2009-like virus)
A/Texas/50/2012 H3N2 for ( A/Victoria/361/2011-like virus)
The Chinese have to clean up their act. Annual threats to the health of the world population are not acceptable in any other area of activity, so why in their chicken raising? (no caps were used in the expression of this idea)
Who knows? If you take the average of the price targets of Lazard, Wedbush, MLV, and FBR, it would be $2.27 billion (10.88/share).
No, I just added it to a list I had made previously. I think that benze_man2002 posted it.
after my last post I briefly passed out, and dreamed of two hands with all thumbs clumsily pounding at a keyboard, but I couldn't make out the message, but I feel that it was vitally important